Other equities analysts have also issued reports about the company. Zacks Investment Research raised Aduro Biotech from a hold rating to a buy rating and set a $13.00 price target for the company in a research note on Tuesday, July 4th. BidaskClub raised Aduro Biotech from a hold rating to a buy rating in a research note on Tuesday, July 25th. Canaccord Genuity set a $30.00 price target on Aduro Biotech and gave the company a buy rating in a research note on Thursday, August 3rd. Cowen and Company initiated coverage on Aduro Biotech in a research note on Tuesday, July 18th. They set an outperform rating for the company. Finally, William Blair reissued an outperform rating on shares of Aduro Biotech in a research note on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $19.14.
Aduro Biotech (ADRO) traded down $0.10 on Tuesday, reaching $7.85. The company’s stock had a trading volume of 406,474 shares, compared to its average volume of 479,327. Aduro Biotech has a one year low of $6.01 and a one year high of $15.52.
Aduro Biotech (NASDAQ:ADRO) last released its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.03). Aduro Biotech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The business had revenue of $3.79 million for the quarter, compared to analysts’ expectations of $4.04 million. During the same quarter in the prior year, the business posted ($0.54) EPS. The business’s revenue for the quarter was up .0% compared to the same quarter last year. equities analysts predict that Aduro Biotech will post -1.28 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://baseballnewssource.com/markets/aduro-biotech-inc-adro-pt-set-at-18-00-by-hc-wainwright/1721958.html.
In other news, insider Thomas W. Dubensky sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $11.38, for a total value of $569,000.00. Following the completion of the sale, the insider now directly owns 80,812 shares of the company’s stock, valued at approximately $919,640.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Blaine Templeman sold 3,557 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $10.99, for a total value of $39,091.43. Following the completion of the sale, the vice president now directly owns 65,275 shares of the company’s stock, valued at $717,372.25. The disclosure for this sale can be found here. Insiders sold a total of 260,334 shares of company stock valued at $2,952,556 over the last ninety days. Corporate insiders own 6.60% of the company’s stock.
Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Aduro Biotech by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock worth $28,637,000 after acquiring an additional 129,079 shares during the last quarter. State Street Corp lifted its stake in shares of Aduro Biotech by 8.3% during the 2nd quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock worth $7,808,000 after acquiring an additional 52,597 shares during the last quarter. Baillie Gifford & Co. lifted its stake in shares of Aduro Biotech by 30.8% during the 3rd quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock worth $5,891,000 after acquiring an additional 130,390 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Aduro Biotech by 15.1% during the 2nd quarter. Northern Trust Corp now owns 453,115 shares of the biotechnology company’s stock worth $5,166,000 after acquiring an additional 59,490 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Aduro Biotech by 283.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock worth $4,244,000 after acquiring an additional 275,295 shares during the last quarter. 34.01% of the stock is owned by hedge funds and other institutional investors.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with our FREE daily email newsletter.